CD19 and precursor B-cell acute lymphoblastic leukemia: Approximately 80% of patients with relapsed or refractory B-ALL (r/r B-ALL) and 40–60% of patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) showed complete responses after anti-CD19 CAR (CAR19) T cell treatment [5, 6, 10, 20–25].